Company University/Non-Profit [Scientist] Type of Agreement Product Area Details (Date)
Abgenix Inc. U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) Research and development collaboration Abgenix XenoMouse technology Abgenix and USAMRIID entered a collaboration in July 1999 to develop antibodies that could potentially protect U.S. troops during biological warfare; USAMRIID received access to Abgenix's XenoMouse technology to make fully human monoclonal antibodies against filoviruses; Abgenix expanded the collaboration, granting USAMRIID further access to its XenoMouse technology to make fully human monoclonal antibodies that will be tested for their ability to provide protection against viral infections attributed to poxviruses (10/99)
Affymetrix Inc. National Cancer Institute Technology access Affymetrix GeneChip technology Agreement allows biomedical research community broad access to Affymetrix's GeneChip probe array technology; volume price discounts are available, with specific terms to be negotiated directly with Affymetrix by each institution; terms designed to not interfere with traditions of publishing and collaboration (4/99)
Affymetrix Inc. University of California Technology access Affymetrix GeneChip technology University of California signed Academic Access deal, which gives preferential access to Affymetrix's standard and custom GeneChip arrays, instrumentation and software to monitor gene expression; terms and conditions specially designed to not interfere with publishing (6/99)
Affymetrix Inc. National Cancer Institute, National Heart, Lung and Blood Institute, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Child Health and Human Development, National Institute of Health Clinical Center Technology access Affymetrix GeneChip technology Agreement allows participating institutes broad access to Affymetrix's standard and custom GeneChip arrays, instrumentation and software to monitor gene expression for use in research activities; terms and conditions specially designed to allow for broad publication of scientific results and to facilitate collaborations with academic, governmental and commercial scientific colleagues (7/99)
Affymetrix Inc. Washington University Technology access Affymetrix GeneChip technology Washington University signed an Academic Access agreement, which gives all Washington University researchers access to Affymetrix's standard and custom GeneChip arrays, instrumentation and software to monitor gene expression for use in research activities (7/99)
Affymetrix Inc. University of Wisconsin, University of Colorado, the Canadian Genetic Diseases Network and the H. Lee Moffitt Cancer Center Academic access agreement Affymetrix's GeneChip technology Affymetrix announced the addition of the four listed entities to its list of AcademicAccess customers; the agreements with each include standard terms and conditions and volume pricing provisions that allow researchers at these facilities broad access to GeneChip technology; further details ND (11/99)
Agritope Inc. University Technologies International Inc. (private technology commercialization company owned by the University of Calgary [Thomas Back] Research collaboration Technology for synthesizing brassinosteroids with high biological activity Back will synthesize compounds in his laboratory and deliver them to Agritope for evaluation and commercial development; Agritope has an option to obtain an exclusive royalty-bearing license to commercialize the technology (6/99)
Agritope Inc. Salk Institute for Biological Studies and the Institute of Cell and Molecular Biology of the University of Edinburgh Research collaboration Functional genomics that uses Agritope's ACTTAG Gene Discovery program to generate genetically modified seed that will be screened for a variety of traits, such as disease resistance, insect resistance, new morphologies, abiotic stress tolerance, improved flowering characteristics, herbicide tolerance and improved nutritional qualities Five-year research program; basic program will be carried out at Agritope; discoveries at both institutes arising from the ACTTAG research will be licensed to Agritope, which plans to seek commercial collaborators (1/99)
Ambrx Inc. Johns Hopkins University [Dr. Randall Reed, Dr. Solomon Snyder, Dr. King-Wai Yu] Technology access agreement Enabling technology and molecules related to chemosensation and olfaction Ambrx signed an exclusive agreement with Hopkins whereby the company will have access to certain key chemosensory proteins and methods from the laboratories of Reed, Snyder and Yu; further details ND (10/99)
Ambrx Inc. Rockefeller University [Dr. Peter Mombaerts] License and research agreement Molecules related to olfaction Ambrx signed an exclusive license and research agreement with Rockefeller University whereby the company will have access to receptors involved in human olfaction for the purpose of building its chemosensory platform; further details ND (10/99)
Ambrx Inc. Harvard University [Dr. Linda Buck, Dr. Catherine Dulac] Option agreement Chemosensory receptors Ambrx signed an exclusive option agreement with Harvard regarding a family of chemosensory receptors discovered by the laboratories of Buck and Dulac; the technology includes the DNA sequences and related proteins of a large multigene family encoding novel mammalian pheromone receptors; further details ND (10/99)
American Biogenetic Sciences Inc. Institute of Laboratory Animal Science of the Chinese Academy of Medical Sciences at Beijing Union Hospital Technology access ABS Antigen-Free Mouse technology The ABS mouse colony will be installed at the Institute of Laboratory Animal Science; the core technology will continue to be housed by ABS at its subsidiary, Stellar Bio Systems Inc.; ABS will allow the use of its technology for development and production of monoclonal antibodies; ABS will have worldwide rights to market, sell and license the antibodies developed (7/99)
American Biogenetic Sciences Inc. Chinese Academy of Medical Sciences and the Institute of Medicinal Plant Development (IMPLAD) Marketing agreement Traditional Chinese herbal medicines American Biogenetics (ABS) and the academy entered an agreement in which ABS will market and sell traditional Chinese medicines worldwide; ABS will have the opportunity to select herbal products and components from IMPLAD's array of products; ABS or its licensees will be permitted to use the academy's seal indicating quality compliance for all medicines produced under the agreement; further details ND (7/99)
Angiotech Pharma ceuticals Inc. University of Pennsylvania License Use of paclitaxel in the treatment of Alzheimer's disease Angiotech acquired an exclusive license to intellectual property that includes U.S. patent No. 5,580,898 (1/99)
Bio-Technology General Corp. Yeda Research and Development Co. Ltd. (licensing arm of The Weizmann Institute of Science in Rehovat, Israel) [Leah Eisenbach] Research and license agreement Peptide-based vaccines for the treatment of cancer; initial efforts to focus on transitional cell carcinoma of the bladder, breast and colon Bio-Technology General will provide research funding and make milestone payments, as well as pay royalties on any peptide-based vaccines resulting from the research which the company markets under the exclusive license (4/99)
Bio-Technology General Corp. Massachusetts General Hospital/Children's Hospital of Boston [Lawrence Weissbach, Valerae Lewis and Michael O'Reilly] Research and license agreement Use of recombinant plasminogen-related peptide as an angiogenesis inhibitor for the treatment of cancer Bio-Technology General will produce rPRP and conduct research at its facility in Rehovat, Israel, in collaboration with Weissbach; the company will fund the research and make milestone payments, as well as pay royalties on resulting therapeutic products that Bio-Technology markets under the exclusive license (4/99)
Antex Biologics Inc. Department of the Army, of the U.S. Department of Defense Development agreement Antex's nutriment signal transduction technology (NST) Antex received a small business technology transfer research contract from the Department of the Army for the development of a multivalent, oral vaccine for traveler's diarrhea, using Antex's NST technology (10/99)
Atairgin Technologies Inc. M.D. Anderson Cancer Center [Gordon B. Mills, Xianjun Fang] Research collaboration Atairgin's platform technology in lysophospholipids Atairgin and M.D. Anderson entered a research collaboration agreement in 1997, using Atairgin's platform technology to develop an early detection marker for ovarian and other gynecological cancers; Atairgin expanded the collaboration, providing for application of its technology to develop potential therapeutic agents (8/99)
Atairgin Technologies Inc. Washington State University Research agreement Fertility and cancer therapeutics Atairgin announced an extensive research collaboration with Washington State to further advance its platform technology to additional therapeutic applications; further details ND (9/99)
Atlantic Pharmaceuticals University of Pennsylvania License agreement Beta-cyclodextrin tetradecasulfate (B-CDT) to prevent restenosis after cardiac angioplasty Atlantic and its subsidiary, Channel Therapeutics Inc., terminated their 6/94 license agreement with University of Pennsylvania (10/99)
Aurora Biosciences Corp. National Cancer Institute (NCI) Technology access Aurora's GenomeScreen technology National Cancer Institute will gain access to Aurora's GenomeScreen technology to identify rare or low abundance transcripts in tumor cells; Aurora will focus on genes that may be missed by other less sensitive gene identification methods (7/99)
Aurora Biosciences Corp. National Cancer Institute Research agreement Aurora's GenomeScreen technology Aurora and the National Cancer Institute (NCI) entered a collaboration to use Aurora's GenomeScreen technology to identify rare or low abundance transcripts in tumor cells (7/99)
Avigen Inc. Children's Hospital of Philadelphia License agreement Factor IX gene therapy using adeno-associated virus Avigen received worldwide rights to Factor IX gene therapy technology for hemophilia B (7/99)
Boston Life Sciences Inc. Hebrew University, Hadassah Medical School License agreement Anticancer fusion toxins Boston Life Sciences will develop, under an exclusive worldwide license, a broadbased technology invented by scientists at Hadassah Medical School covering fusion toxins for the treatment of a wide variety of solid tumors, as well as multiple sclerosis and allergies (6/99)
Boston Biomedica Inc. Consortium for Plasma Science LLC Development and commercialization BBI's Pressure Cycling Technology for the inactivation of pathogens and other infectious agents in human source plasma Consortium will provide initial funding to cover BBI's research efforts, with subsequent funding contemplated during the first half of 2000 and annually thereafter based on meeting milestones; BBI will pay consortium a royalty on future sales (12/99)
CalBioMarine Technologies Inc. University of California, San Diego (UCSD) License agreement Technologies for materials and methods for production of polyketides CalBioMarine signed a technology license agreement with UCSD for an exclusive license to technologies for materials and methods for the production of polyketides such as the bryostatins developed at UCSD's Scripps Institution of Oceanography (8/99)
Calypte Biomedical Chinese National Center for AIDS Prevention and Control, and Chinese Academy of Preventive Medicine Distribution agreement Non-invasive urine HIV test Calypte's test selected for widescale use within the Chinese healthcare system, including the Chinese Academy of Preventive Medicine, which will use the product exclusively (3/99)
Celgene Corp. National Cancer Institute Collaboration agreement Thalomid Celgene and the NCI initiated a Phase II trial using Celgene's Thalomid to treat patients with colorectal cancer (8/99)
ChromaVision Medical Systems Inc. University of Southern California, Kenneth Norris Jr. Comprehensive Cancer Center [Roscoe D. Atkinson] Development agreement Automated Cellular Imaging System test for angiogenesis ChromaVision commenced a clinical partnership to develop an objective tumor angiogenesis test with Atkinson and the university cancer center (9/99)
Cel-Sci Corp. Johns Hopkins University [Dr. Noel Rose] Collaboration agreement Cel-Sci's immune system technology Cel-Sci and Hopkins entered a collaborative study using Cel-Sci's ligand epitope antigen presentation system (LEAPS) and antigen directed apoptosis (AdapT) technologies for the treatment of autoimmune myocarditis (11/99)
Chiron Corp. Norwegian Institutes of Public Health (NIPH) Development agreement Combination vaccine against Neisseria meningitidis Chiron and NIPH entered a development agreement for a combination vaccine using Chiron's conjugate vaccine against meningococcal B disease, and NIPH's vaccine against meningococcal B; Chiron will market the new combination vaccine, as well as NIPH's vaccine, in countries outside of Norway (11/99)
Chiron Corp. Australian Red Cross Blood Service Product use contract Chiron's nucleic acid testing system to screen blood supplies for hepatitis C and HIV-1 viruses Combination test, developed and manufactured by GenProbe Inc., is expected to be fully implemented in Australia by mid-2000; Chiron's Australian subsidiary will assist in implementation (12/99)
Ciba Vision (a unit of Novartis AG, Switzerland) University of Iowa and UniversitT Louis Pasteur (France) Research collaboration Biological causes and potential treatments for age-related macular degeneration (AMD) Ciba, University of Iowa and the eye clinic of UniversitT Louis Pasteur entered a collaborative research agreement to identify the biological causes and potential treatments for AMD and other retinal degenerations; Ciba received the opportunity to license University of Iowa patents, including intellectual property developed prior to or during the collaboration (9/99)
Digene Corp. Mexican National Institute of Public Health, the Mexican Institute for Social Security and the Johns Hopkins School of Public Health Clinical trial collaboration Evaluation of Digene's human papillomavirus test as a primary cervical cancer screening to determine if screening will result in improved and more costeffective cervical cancer prevention; trial will enroll 7,500 women Financial details ND (1/99)
Digital Gene Technologies Johns Hopkins University School of Medicine and the Jackson Laboratory Technology access DGT's TOGA gene expression profiling technology DGT, Johns Hopkins and Jackson Laboratory will collaborate in an expanded study of neurodegenerative disease using DGT's TOGA (Total Gene Expression Analysis) technology; the collaboration is under the direction of the DGT scientific advisory board, and is designed to advance basic research and encourage publication, with commercial opportunities reserved for DGT (8/99)
Diversa Corp. Bermuda Biological Station for Research Inc. Bioprospecting Sample collection from Bermuda's marine habitats Diversa and BBSR scientists will collect samples, initially focusing on discovery of recombinant biomolecules from symbiotic bacteria living in sponges, tunicates and other marine life (10/99)
Endocyte Inc. National Cancer Institute (NCI) Collaborative Research and Development Agreement (CRADA) Use of the vitamin folate to deliver chemotherapeutic drugs to cancer cells Endocyte will select compounds from NCI's repository of anticancer drugs to link to folate; NCI and Endocyte will jointly test the resulting compounds (5/99)
EntreMed Inc. National Cancer Institute (NCI) Collaborative Research and Development Agreement (CRADA) Use of 20methoxyestradiol (2ME2) as an anticancer agent (angiogenesis inhibitor) EntreMed scientists will provide 2ME2 to the NCI for collaborative studies in preclinical pharmacology, toxicology, and anticipated clinical trials; together with NCI, the company will design, review and interpret the results of preclinical studies required for investigational new drug application (4/99)
EntreMed Inc. Children's Hospital, Boston [Judah Folkman] Research agreement EntreMed's Endostatin and Angiostatin proteins EntreMed extended its 9/93 research agreement with Folkman's laboratory at Children's Hospital, Boston; EntreMed will continue to fund certain research projects and will have rights to discoveries arising from them; scientists and technicians in Folkman's laboratory will provide research support related to upcoming clinical trials of Endostatin protein and Angiostatin protein (6/99)
Genomica Corp. University of Oxford (UK) License agreement Genomica's Discovery Manager pharmacogenomic software Genomica licensed its software to the University of Oxford to facilitate its genome screening program; terms of the agreement ND (8/99)
Genomica Corp. Wellcome Trust Centre for Human Genetics License agreement Genomica's Discovery Manager pharmacogenomic software Genomica licensed its software to the Wellcome Trust Centre for genetic analysis in support of bioinformatics within the centre; terms of the agreement ND (8/99)
GenoPlex Inc. Massachusetts General Hospital [Rudolph Tanzi] License Discoveries related to a2macroglobulin (a2M) genes variants linked to Alzheimer's disease GenoPlex exclusively licensed several patent applications related to the diagnosis and treatment of diseases associated with a2M, and is using the technology in its Alzheimer's program (3/99)
Gen-Probe Inc. and Chiron Corp. America's Blood Centers Technology evaluation agreement Use of TranscriptionMediated Amplification, a technology for nucleic acid testing developed by Gen-Probe and marketedby Chiron; allows for simultaneous testing of HIV-1 and hepatitis C virus RNAs Chiron, Gen-Probe and ABC are co-sponsors of studies designed to evaluate TMA technology; Chiron and Gen-Probe will supply instrumentation and reagent kits to ABC, which will conduct this testing at multiple centers nationwide (3/99)
Gen-Probe Inc. and Chiron Corp. American Red Cross Technology evaluation agreement Use of Transcription Mediated Amplification, a technology for nucleic acid testing developed by Gen-Probe and marketed by Chiron; allows for simultaneous testing of HIV-1 and hepatitis C virus RNAs Gen-Probe and Chiron will provide instruments and nucleic acid testing kits to the Red Cross, which will conduct the testing at the organization's National Genome Testing Laboratory in San Diego (1/99)
Genset SA (France) Johns Hopkins University School of Medicine [Ann Pulver] Research collaboration Identification and cloning of schizophrenia susceptibility genes; collaboration uses of Genset's single nucleotide polymorphism technology (densely spaced sets of proprietary biallelic markers) and linkage disequilibrium association strategies for analysis of a Johns Hopkins bank of 1,800 DNA samples collected from more than 300 families containing one or more members diagnosed with schizophrenia Two-year research agreement granting Genset access to bank DNA samples from families with one or more schizophrenic members (5/99)
Genset SA (France) Commissariat a l'Energie Atomique (CEA) Development agreement Genotyping technology Genset and the CEA entered a collaboration for the development of a largecapacity genotyping microprocessor; the agreement provides that Genset and the CEA will each be able to use the results of their collaboration program in their internal research programs; the two parties will cooperate to commercialize the results, either through a joint venture or with other partners; in the event the parties use the results independently, Genset will have commercial exclusivity in the field of genotyping, other fields being open to commercialization by the CEA (11/99)
Genzyme Corp. The Toronto Hospital [Richard Weisel] Research and development collaboration Use of cell-based therapy to treat cardiovascular disease; research will focus initially on developing a treatment that uses cultured autologous cardiomyocyte, to replace damaged heart tissue Genzyme acquires rights to all intellectual property and technology relating to existing cardiomyocyte and cell therapy research performed by Weisel and associates, and will solely own or have access to all new technology produced by the collaboration; Genzyme paid an undisclosed up-front fee to acquire the rights noted above and for an option to license additional technologies developed outside the collaboration; Genzyme will also make milestone and royalty payments on covered products (1/99)
Genzyme General Beth Israel Deaconess Medical Center Research and development agreement DHA-based therapy for cystic fibrosis (CF) Genzyme and researchers at Beth Israel entered a collaboration to develop a cystic fibrosis therapeutic based on the discovery by Beth Israel researchers of a correctable lipid imbalance in a mouse model of CF; Genzyme has been granted an exclusive license to intellectual property related to DHA therapy (10/99)
Genzyme Molecular Oncology Children's Hospital Medical Center in Boston [Judah Folkman and Michael O'Reilly] License Anti-angiogenic protein for use in treating cancer In exchange for an exclusive wordwide license, GMO will pay an upfront fee, make milestone payments and pay royalties on sales (1/99)
Hyseq Inc. Imperial Cancer Research Technology Ltd. (wholly owned subsidiary of Imperial Cancer Research Fund in the UK) License Use of naturally soluble forms of human ectoapyrases as anti-clotting agents Hyseq acquired certain exclusive rights; further details ND (2/99)
ICAgen Inc. Research Foundation of State University of New York, Stony Brook (SUNY) License agreement Ion channel disease targets ICAgen received an exclusive license from SUNY for novel ion channel genes, discovered by university researchers; further details ND (6/99)
IDEC Pharmaceuticals National Cancer Institute [Ira Pastan] Cooperative Research and Development Agreement Development and therapeutic use of prostatespecific PAGE antigens in therapeutic vaccines for prostate cancer; vaccines will employ IDEC's Provax adjuvant to induce cytotoxix T lymphocyte responses to tumorassociated antigens IDEC will collaborate on further studies of PAGE antigens with Pastan's laboratory, in which the family of antigens was discovered; further details ND (2/99)
IDEC Pharmaceuticals University of California [Chris Hughes] Research collaboration Identification of genes specifically expressed by tumor endothelium in order to find antiangiogenic targets for treating cancer IDEC will collaborate with Hughes' laboratory; details ND (2/99)
IDEC Pharmaceuticals National Cancer Institute Collaboration agreement IDEC's Zevalin radioimmotherapy treatment IDEC and the NCI entered a collaboration to broaden clinical studies of Zevalin (ibritumomab tiuxetan) as treatment for conditions outside those currently under investigation by IDEC (8/99)
IGEN International Inc. John Wayne Cancer Institute [Dave Hoon] Expanded research collaboration Use of IGEN's Origen technology to develop diagnostics, especially for cancer; Hoon has already developed a blood test for early detection of micrometastases IGEN expanded the collaboration to focus on additonal cancer diagnostics for early detection and monitoring of progression; IGEN obtained an option to exclusively license any tests developed by Hoon (1/99)
Immune Response Corp. University of Maryland Biotechnology Institute (Institute of Human Virology) [Robert Gallo] License Use of 2 technologies to potentially treat a variety of diseases; one centers on hCG associated factor (HAF), a naturally occurring peptide that may have applications in cancer (by promoting bone marrow growth differentiation) and in HIV prevention and treatment; the 2nd centers on chemokine technology Immune Response will issue restricted stock to UMBI as an initial license fee, will sponsor a 5-year renewable research program at IHV, and will initiate a research effort of its own at the UMBI facility; Immune Response will have a right of first refusal to license all new technology related to HAF and chemokines that is subsequently developed by IHV; Immune Response agreed to use all reasonable efforts to commercialize products and will incur patenting costs (5/99)
Immunicon Corp. The University of Texas Southwestern Medical Center [Jonathan W. Uhr] Research and license agreement Immunicon's rare-cell detection and analysis platform technologies The research agreement is for a period of three years and provides monetary support and other consideration for research into applications and further development of Immunicon's platform technologies for the diagnosis, staging, treatment and monitoring for recurrence of invasive cancers of epithelial origins; the license agreement grants Immunicon an exclusive worldwide license for commercialization of technology developed under the research agreement; Uhr will act as principal investigator (8/99)
ImmunoGen Inc. Duke University and Johns Hopkins University License agreement ImmunoGen's TumorActivated Prodrug (TAP) technology ImmunoGen purchased an option from Duke and Hopkins to license a novel, cancer-targeting antibody, developed by investigators at the two institutions, for exclusive use with its TAP technology; terms ND (11/99)
Immunomedics Inc. National Cancer Institute [Susanna Rybak] Cooperative Research and Development Agreement Development and use of antibody-conjugated recombinant cytotoxic ribonucleases as a potential new class of anticancer agents; could potentially be directed against both blood cancers and solid tumors NCI will contribute special recombinant toxins that destroy the cancer cells' RNA; Immunomedics will contribute antibodies, drugs and certain peptides, which target various cancers; the company will collaborate on studies with NCI's research team and will retain commercial rights (2/99)
Incyte Pharmaceuticals Inc. Huntsman Cancer Institute Research collaboration Incyte's LifeSeq Gold database Incyte and Huntsman entered a twoyear collaboration to study the role of genes in the diagnosis, prevention and treatment of cancer; Huntsman will have access to Incyte's LifeSeq Gold database, as well as the use of Incyte's microarrays and microarray data management software; Incyte will receive access to highquality tissue and tumor samples, as well as research findings from Huntsman's colon cancer program (9/99)
Incyte Pharmaceuticals Inc. University of Washington Research agreement DNA sequencing Incyte and the University of Washington entered a collaboration in which Incyte will perform DNA sequencing and provide data to the university; the University of Washington Genome Center will refine the data and deposit it, at varous stages, into Genbank, the publicly accessible collection of data from the Human Genome Project (11/99)
Inhibitex Inc. BioResearch Ireland (national agency commercializing biotechnology research from Irish universities) [Timothy Foster] Research and license agreement Discovery and characterization of cell surface adhesions from Staphylococcus aureus and coagulase-negative staphylococci Inhibitex will use novel adhesions discovered in the collaboration to to develop its pipeline of immunotherapeutics targeting the prevention and treatment of hospitalacquired, antibiotic-resistant staphylococcal infections; research will be conducted at BI's National Pharmaceutical Biotechnology Centre and at the Moyne Institute of Preventive Medicine (both at Trinity College in Dublin) (4/99)
Inhibitex Inc. University of Pavia in Italy Research and license agreement Use of the university's existing library of proprietary monoclonal antibodies to develop products to treat various antibioticresistant infections Inhibitex gains worldwide rights to the library, as well as to future discoveries resulting from the collaboration, in the field of treatments for resistant infections (1/99)
Inhibitex Inc. University of Minnesota [Margaret Hostetter] License Use of MSCRAMM (microbial surface components recognizing adhesive matrix) surface proteins from Candida albicans for developing vaccines to prevent fungal infections caused by the organism Inhibitex exclusively licensed rights to the protein; further details ND (6/99)
Inhibitex Inc. Red Cross Foundation Central Laboratory (ZLB, a foundation of the Swiss Red Cross) Collaboration agreement Antibody-based products to treat antibiotic-resistant S. aureus infections Inhibitex and ZLB entered an agreement to collaborate on the development of antibody-based products to treat and prevent antibiotic-resistant S. aureus infections; Inhibitex will receive an up-front cash payment and funding to cover research and development of its antibody-based technology; upon achieving specific preclinical development milestones, Inhibitex and ZLB will negotiate an agreement to commercialize products based on both monoclonal and polyclonal antibodies; if the program and the agreement expand, ZLB will obtain worldwide manufacturing rights and marketing rights for Europe and the Middle East, as well as rights covering polyclonal antibody-based products in Asia; in exchange for these rights and upon completion of the agreement, Inhibitex will receive additional cash payments, as well as further research support and royalties on sales; Inhibitex will also retain marketing rights to the antibodybased technologies in North America and all other areas, excluding those specifically as
InSite Vision Inc. University of California Option agreement Use of TIGR gene technology for the treatment and prevention of glaucoma InSite signed option agreement for therapeutic rights to issued and pending gene patents and applications; TIGR had previously licensed diagnostic and prognostic rights; financial terms ND (4/99)
InSite Vision Inc. Uppsala University, Sweden [Claes Wadelius] Research agreement InSite's ISV-900 program InSite and Wadelius signed a glaucoma genetic research agreement that covers investigation on the role of the TIGR gene in primary open angle glaucoma and exfoliative glaucoma patients in a Swedish population; Wadelius will have access to InSite's ISV-900 program, which is designed to explore various use of the TIGR gene and other glaucoma genes for glaucoma diagnosis, prognosis, therapeutic development and disease management (9/99)
Invitrogen Corp. Novartis Institute for Functional Genomics Research collaboration Advanced cloning technologies and expression systems, including TOPO and Echo System cloning technologies NIFG will use Invitrogen's technologies to develop new reagents to facilitate its research; Invitrogen receives rights to sell clones and reagents generated by these collaborative efforts to the research community (12/99)
Layton Bioscience Children's Medical Center, Boston [Evan Snyder] Research and development collaboration Neural stem cell technology Layton gained exclusive worldwide rights to research and develop applications of the technology (12/99)
Lexicon Genetics Inc. Rockefeller University Research agreement Engineering of custom knockout mice Lexicon and Rockefeller entered a multi-year functional genomics research agreement for the rapid engineering of custom knockout mice; under the agreement, researchers in the laboratory for which the agreement was made may specify genes for which Lexicon will produce knockout mice using its technologies in homologous recombination, including Cre-lox, positive/negative selection and isogenic DNA; Lexicon will share in commercial applications of gene function discoveries made under the agreement; financial terms ND (8/99)
Lexicon Genetics Inc. Johns Hopkins University Research collaboration Lexicon will create custom knockout mice for gene of interest using homologous recombination technologies Financial terms ND, though company said academic collaborations allow for ¿significant potential downstream benefits¿ (6/99)
Lexicon Genetics Inc. Pennsylvania State University Research collaboration Lexicon will create custom knockout mice for gene of interest using homologous recombination technologies Financial terms ND, though company said academic collaborations allow for ¿significant potential downstream benefits¿ (6/99)
Lexicon Genetics Inc. University of Southern California Research collaboration Lexicon will create custom knockout mice for gene of interest using homologous recombination technologies Financial terms ND, though company said academic collaborations allow for ¿significant potential downstream benefits¿ (6/10)
Lexicon Genetics Inc. University of Rochester Research collaboration Lexicon will create custom knockout mice for gene of interest using homologous recombination technologies Financial terms ND, though company said academic collaborations allow for ¿significant potential downstream benefits¿ (6/10)
Lexicon Genetics Inc. Indiana University School of Medicine Research collaboration Lexicon will create custom knockout mice for gene of interest using homologous recombination technologies Financial terms ND, though company said academic collaborations allow for ¿significant potential downstream benefits¿ (6/10)
Lexicon Genetics Inc. The Max Planck Society Research collaboration Lexicon will create custom knockout mice for gene of interest using homologous recombination technologies Financial terms ND, though company said academic collaborations allow for ¿significant potential downstream benefits¿ (6/10)
LifeCell Corp. University of Texas M.D. Anderson Cancer Center and Pharmacia & Upjohn (P&U) Collaborative study agreement LifeCell's Thrombosol LifeCell, M.D. Anderson and P&U initiated a study of ThromboSol focusing on safety and clinical efficacy; terms of the agreement ND (7/99)
LigoCyte Pharmaceuticals Department of Defense Research agreement Biodefense technology LigoCyte will receive $1.5M in federal funding for research of biodefense measures that seek to identify and prepare to deal with infectious agents and their toxins in the environment, including E. coli, the Norwalk virus and brucellosis (10/99)
Lorus Therapeutics Inc. National Cancer Institute Development collaboration Novel anticancer compounds Lorus announced an extension of a previous collaboration with the NCI, which has agreed to allocate resources for the further development of three anticancer compounds initially discovered at Harvard Medical School; further details ND (10/99)
Maxygen Inc. California Institute of Technology [Frances Arnold] License and research collaboration Use of Staggered Extension Process directed evolution technology developed in Arnold's lab; technology has appli cations in Maxygen's ¿DNA Shuffling¿ programs for nucleic acid recombination Maxygen obtained exclusive worldwide license and research collaboration; further details ND (4/99)
MedImmune Inc. Columbia University License agreement and research collaboration Columbia's MAb 15A10 catalytic antibody against cocaine addiction MedImmune will develop and commercialize Columbia's 15A10 antibody to treat cocaine overdose and addiction; MedImmune will be responsible for worldwide research, clinical development, manufacturing and commercialization of any product resulting from the collaboration; MedImmune will pay a one-time license fee to Columbia, and will make milestone and royalty payments based on clinical development progress and sales of resulting products; Ixsys Inc. will optimize the primary product candidate as part of the four-product antibody alliance it entered into with MedImmune in 2/99 (9/99)
Millennium Pharmaceuticals Inc. Partners HealthCare System Inc. (affiliate of Harvard University Medical School) Research collaboration Creation of a series of long-term research collaborations in gene discovery and target identification; Millennium also gains ability to clinically validate drugs and diagnostics A comprehensive research plan will be established annually; Millennium will use its drug discovery platform to advance mutual scientific interests, and will make available to partners various technologies; Partners will provide assays, tissue samples, animal models and clinical and research expertise; financial details ND (3/99)
MitoKor Indian Institute of Science in Bangalore Sponsored research Synthesis of novel intermediates for drug discovery MitoKor will support a team of organic chemists at IIS, who will synthesize novel intermediates for MitoKor; the collaboration will expire in one year, but may be extended by mutual agreement; MitoKor has rights to compounds developed in the program and IIS retains rights to certain synthetic processes (2/99)
Nanogen Inc. Mayo Clinic Beta testing site agreement Testing of Nanogen's molecular identification system for analyzing single nucleotide polymorphisms and repetitive DNA sequences Terms ND (3/99)
Nanogen Inc. Bode Technology Group Beta testing site agreement Testing of Nanogen's molecular identification system for analyzing single nucleotide polymorphisms and repetitive DNA sequences Terms ND (3/99)
Nanogen Inc. University of Texas Southwestern Medical Center at Dallas Beta testing site agreement Testing of Nanogen's molecular identification system for analyzing single nucleotide polymorphisms and repetitive DNA sequences Terms ND (3/99)
NeoTherapeutics Inc. University of California, Irvine (UCI) [Olivier Civelli] Collaborative research and technology development agreement UCI's orphan receptor strategy research technique NeoTherapeutics will conduct research with a UCI team headed by Civelli on neurotransmitters and their receptors in the brain; the company awarded Civelli's team $0.9M for three years; NeoTherapeutics will make additional investments totaling $1.1M for further development of the optioned technology; the company may enter strategic partnerships with larger pharmaceutical companies to create drugs from the research and development efforts conducted under the collaboration; the company also will have an option for an exclusive three-year license to work on developing drugs that stem from findings of the UCI team (9/99)
Neurologic Inc. National Institutes of Health (NIH) License agreement Diagnostic test for Alzheimer's disease NeuroLogic acquired an exclusive worldwide license from NIH for a diagnostic test for Alzheimer's; NeuroLogic will also own rights to the technology underlying the test; terms of the agreement ND (9/99)
Novavax Inc. University of Michigan Supply agreement Novavax's proprietary microbicides Novavax received an extension of its subcontract to supply the University of Michigan with its proprietary microbicides for the development of antimicrobial products against certain biologic warfare agents; the program is funded by the Defense Advanced Research Projects Agency of the U.S. Department of Defense (8/99)
Ontogeny Inc. University of California/San Francisco [Ervin Epstein] Research collaboration Ontogeny will evaluate therapetic potential of compounds to treat basal cell carcinoma using a model of the disease developed at UCSF Terms ND (3/99)
Ontogeny Inc. Brigham and Women's Hospital and the Center for Cutaneous Oncology at the Dana-Farber Cancer Institute Research collaboration Elucidation of molecular pathways involved in basal cell carcinoma and identification of potential therapeutics The Division of Dermatology at BWH and the Center for Cutaneous Oncology at DFCI will provide expertise in cell culture and transgenic animals, and human basal cell carcinoma cells; Ontogeny will use the cells to define further the role of the patched protein in the development of the disease, and will use the cells and tissue samples to evaluate leads (3/99)
OraPharma Inc. Children's Medical Center Corp. Separate license and sponsored research agreements License is for manufacture and sale of Children's Medical products for bone and soft tissue regeneration for the dentistry and orthopedics markets: OsteoIntegrin, OsteoMorphin and RIS (Rapid Implant Stabilizer); under sponsored research agree ment, Children's Medical will perform R&D activities based on bone and tissue regeneration and wound healing technologies OraPharma gains exclusive worldwide license to manufacture and sell 3 products; OraPharma has exclusive worldwide license to manufacture and sale of products developed under research agreement (2/99)
Ortec International Inc. Massachusetts Institute of Technology and Tufts University [Lisa Freed and Gordana VunjakNovakovic (MIT); David Kaplan (Tufts)] Research collaboration Ortec's CCS colla gen sponge Collaboration will use Ortec's collagen sponge as the scaffold for the growth of various types of cells, especially heart tissue, but also striated muscle, nerve ligament, blood vessels, bone, cartilage and tendon; Ortecs will receive worldwide rights to license any technology resulting from collaboration (12/99)
Oxford BioMedica plc University of Maastricht [Hennie Hoogenboom] Technology rights acquisition OBAb2, a human antibody for cancer immunotherapy Oxford BioMedica acquired rights to antibody (12/99)
Oxigene Inc. Arizona State Universisty License agreement Arizona State's combretastatin technology Oxigene acquired an exclusive, worldwide license for the commercial rights to Arizona's combretastatin technology, including the lead compound, Combretastatin A-4; further details ND (8/99)
Pharmacopeia Inc. Harvard University (Institute of Chemistry and Cell Biology) Research collaboration Use of Pharmacopeia's platform for small-molecule combinatorial chemistry ECLiPS Pharmacopeia scientists will conduct research at ICCB, in addition to sharing technology; further details ND (3/99)
PolyGenyx Inc. Massachusetts Institute of Technology [John Landers] Licensing agreement OmniScan genotyping technology for rapid, low-cost discovery of single nucleotide polymorphisms and their genotyping PolyGenyx signed an exclusive licensing agreement for OmniScan, with the intention of using it for drug discovery, pharmacogenomics and DNA fingerprinting applications, as well as marker-assisted selection for agriculture applications (12/99)
ProScript Inc. National Cancer Institute (NCI) Cooperative Research and Development Agreement Development of ProScript's anticancer agent and proteasome inhibitor, PS-341, which targets protein degradation machinery NCI will sponsor several Phase I clinical trials through the Cancer Therapy Evaluation Program (1/99)
Protein Sciences Corp. Texas A&M University [Max Summers and Gale Smith] Agreement to combine intellectual property and know-how; Protein Sciences may sublicense technologies to third parties Use of baculovirus expression vector system for protein production to third parties; Texas A&M Deal combines Texas A&M's patents with Protein Sciences' commercial-scale expression technology, with the goal of sublicensing combined platform will continue to work directly with licensees whose products would not benefit from the added value of Protein Sciences' production technologies (2/99)
Protein Sciences Corp. Texas A&M University Collaboration agreement Baculovirus expression vector system (BEVS) Protein Sciences and Texas A&M signed a definitive agreement to combine their intellectual property and know-how regarding BEVS; Protein Sciences is exclusively authorized to sublicense the combined BEVS technology to third parties in combination with its own proprietary technology (6/99)
Quark Biotech Inc. New York Blood Center [Jan Visser] Research and license agreement Stem cell research Quark and the New York Blood Center (NYBC) signed a collaborative research and licensing agreement to identify genes implicated in hemopoietic stem cell differentiation; Quark will gain access to various purified stem cell subpopulations provided by Visser; Quark will apply its gene discovery technology platform to the stem cells to identify genes and proteins that are expressed during the stem cell differentiation process; terms of the agreement ND (8/99)
Renaissance Cell Technologies (a subsidiary of Incara Pharmaceuticals Corp.) University of North Carolina, Chapel Hill [Lola M. Reid] License agreement Isolation and purification of human liver progenitor cells Renaissance licensed the exclusive, worldwide rights to patent applications and related technologies for isolating and purifying human liver progenitor cells, developed by Reid at UNC's school of medicine under a previous sponsorship agreement (8/99)
Repligen Corp. National Cancer Institute Clinical trial agreement Repligen's CTLA4-Ig compound for selective immune response inhibition Repligen and NCI entered a clinical trial agreement for a Phase II trial of CTLA4-Ig, evaluating the compound's ability to prevent the development of graft-vs.-host disease in patients undergoing unmatched donor bone marrow transplants; NCI will submit an IND for the drug and sponsor the trial; Repligen will provide the CTLA4-Ig and will support laboratory measurements designed to confirm the drug's effect and the specificity of the induced immune tolerance (9/99)
SciClone Pharmaceuticals University of California, Berkeley [Edward T. Wei] License agreement Class of immunomodulating compounds developed by Wei SciClone licensed the exclusive rights to a class of compounds developed by Wei; further details ND (8/99)
SciClone Pharmaceuticals National Institutes of Health (NIH) License agreement DAX protein repair therapy for cystic fibrosis SciClone acquired the rights to DAX from NIH; the company plans to pursue fast-track and orphan drug designation from the FDA, and development grants; terms of the acquisition ND (10/99)
Select Therapeutics Inc. Institut Curie (France) Expansion and extension of research and development agreement Cancer vaccine technology relating to antigen presentation to dendritic cells Select gains exclusive license to option the basic intellectual property relating to antigen presentation to dendritic cells (12/99)
Sequenom Inc. University of Munster (Germany) Technology access Sequenom's MassArray SpectroChips technology The University of Munster received access to Sequenom's MassArray and SpectroChips technology for genetic research in cardiovascular diseases; further details ND (9/99)
Sequenom Inc. National Cancer Institute System installation Sequenom's MassArray system for single nucleotide polymorphism analysis System installed at NCI's Advanced Technology Center in Gaithersburg, Md. (12/99)
SignalGene Inc. McGill University Research collaboration Role of nuclear receptors in complex genetic diseases, especially obesity and diabetes SignalGene invested C$0.25M in project to discover drug targets and receives a timelimited option for an exclusive license to any discoveries made under the project (12/99)
StressGen Biotechnologies Corp. National Cancer Institute Clinical trial agreement StressGen's HspE7 for the treatment of human papillomavirus (HPV) StressGen and NCI entered a clinical trial agreement for the co-development of HspE7; NCI's division of cancer treatment and diagnosis will work collaboratively with StressGen to develop a general plan for clinical development of the drug, and then solicit clinical research protocols from independent investigators and cooperative research groups affiliated with NCI (11/99)
SuperGen Inc. US Oncology Research agreement SuperGen's rubitecan and nipent anticancer compounds SuperGen and US Oncology entered a collaboration in which US Oncology will carry out clinical programs using SuperGen's anticancer compounds; further details ND (9/99)
SuperGen Inc. Stehlin Foundation for Cancer Research Research agreement Anticancer compounds SuperGen and Stehlin extended their 1997 research agreement whereby SuperGen acquired global rights to other camptothecins and additional anticancer compounds; in addition, reductions will be made with respect to SuperGen's royalty payments for sales of rubitecan above $500M (11/99)
SuperGen Inc. Clayton Foundation for Research, Houston Licensing and research agreement Inhaled versions of formulations of camptothecins (including rubitecan) and taxanes (including paclitaxel) SuperGen gained worldwide rights to inhaled versions of camptothecin (12/99)
Synsorb Biotech Inc. Consortium that includes the Canadian Bacterial Disease Network, the Canadian Microbiology Consorium Inc., the University of Alberta, the University of British Columbia, and Novadex Pharmaceuticals Ltd. License agreement Use of compounds for the treatment of lung complications associated with cystic fibrosis; carbohydrate-based compounds appear to reduce viscosity of mucous and inhibit proliferation of bacteria in the lungs of CF patients Details ND (6/99)
Third Wave Technologies Stanford University Research collaboration agreement Third Wave's Invader platform technology for DNA and RNA analysis Stanford's Human Genome Center will have access to Third Wave's proprietary assay development tools for largescale development of Invader-based pharmacogenomic assays for use at both the Genome Center and the university; all Stanford researchers will have broad access to the technology for single nucleotide polymorphism, genotyping and gene expression analysis; Stanford will receive preferential pricing for certain reagents for both its pharmacogenomic research and clinical applications; Third Wave will receive certain rights to all discoveries made using its technology; the agreement includes special terms and conitions designed to allow academic researchers freedom to collaborate with others and publish scientific results (10/99)
Third Wave Technologies University of Guelph (Canada) and Health Canada Research and license agreement Third Wave's Invader technology Third Wave, University of Guelph and Health Canada entered a research and license agreement for the detection and typing of verocytotoxin-producing E. coli; Guelph and Health Canada will have access to Third Wave's technologies for developing assays; Third Wave has an option to obtain exclusive worldwide commercial rights to the developed technology; the agreement includes other terms and conditions designed to promote academic researchers' freedom to collaborate and publish scientific results (10/99)
Variagenics Inc. McGill University [Rima Rozen] License agreement Use of methylenetetrahydrofolate reductase gene for diagnostic and therapeutic purposes; variations are associated with cardiovascular disease; tests would have utility in early diagnosis and selection of patients for whom treatment with folate would reduce risk Variagenics licensed exclusive rights; further details ND (4/99)
VaxGen Inc. Centers for Disease Control and Prevention (CDC) Clinical trial agreement HIV vaccine The CDC will contribute funds to support additional research at five of the 56 clinics in the U.S. currently conducting Phase III trials of VaxGen's AIDSvax vaccine; the CDC will contribute $2M annually, for four years, to the clinics (10/99)
Viragen Scotland Ltd. (subsidiary of Viragen Europe Ltd.) Research arm of Memorial SloanKettering Cancer Center [Alan Houghton, Philip Livingston,and Paul Chapman] Research and development collaboration Monoclonal antibody treatment for melanoma and certain other cancers; to be tested as monotherapy and in combination with Viragen's Omniferon alpha interferon product Viragen will work with MSKCC to produce and manufacture a human monoclonal antibody, which MSKCC will then use in clinical trials; MSKCC agreed to underwrite and coordinate Phase I and II trials (12/99)
Virax Holdings Ltd. CSIRO License agreement Fowl pox virus vector technology Virax gains exclusive rights to use the CSIRO vector technology in HIV/AIDS applicacations, and in other human health problems in conjunction with Virax's Co-X-Gene technology, a co-expression method wherein antigens and cytokines are produced simultaneously (9/99)
VistaGen Inc. National Jewish Medical and Research Center (NJMRC) [Gordon Keller] License agreement NJMRC's embryonic stem cell patents and technology VistaGen licensed certain exclusive, worldwide rights to embryonic stem cell patents and technology developed by Keller; VistaGen will use the technology to develop embryonic stem cells as a platform for increasing the efficiency of drug discovery and development; further details ND (7/99)
VitaResc Biotech AG (Germany) Scottish National Blood Transfusion Service License agreement Anti-lipopolysaccharide drug for the treatment of systemic inflammatory response (SIRS) VitaResc received exclusive worldwide rights from the Scottish National Blood Transfusion Service (SNBTS) to develop an anti-lipopolysaccharide drug resulting from a joint research effort between SNBTS and Novartis; Novartis has retained a first right of negotiation to re-enter into the development of the antibody when certain milestones have been achieved by VitaResc (10/99)
Vysis Inc. National Human Genome Research Institute (NHGRI) and the Institute of Pathology at the University of Basel (Switzerland) Research and development agreement Vysis's GenoSensor and Fluorescence In Situ Hybridization (FISH) systems, NHGRI's tissue microarrays and the university's tumor specimen collection The three institutions will combine their technologies and products to define amplifications of specific genes in various cancers to determine their potential clinical significance; Vysis has an option to negotiate a license with the National Institutes of Health and/or the University of Basel for inventions that arise from the collaboration (6/99)
Xanthon Inc. North Carolina State University (NCSU) [H. Holden Thorp and Neena Grover] License agreement NCSU's process of cleaving nucleic acids with oxoruthenium complexes Xanthon licensed exclusive, worldwide rights from NCSU to patented technology develped by Thorp and Grover; the technology will have commercial applications in future Xanthon products; further details ND (10/99)
Xanthon Inc. North Carolina State University, Raleigh (NCSU) Research agreement Electron transfer reactions Xanthon entered into a sponsored research agreement with NCSU for the characterization of electron transfer reactions at indium/tin oxide electrode interfaces; the project is intended to provide information relative to the Xanthon Xpression analysis system (10/99)
ZymeTx Inc. Oklahoma Medical Research Foundation (OMRF) License and development agreement OMRF's ZX-0851 anti-HIV compound ZymeTx returned its license to ZX0851 to OMRF, citing a longer development cycle than originally planned; in return for the license, OMRF will reimburse ZymeTx for its license fee and certain other expenses related to the compound; the return of the license does not affect other, current collaborations between OMRF and ZymeTx (7/99)